iScience (Jul 2023)

Pharmacological HDAC inhibition impairs pancreatic β-cell function through an epigenome-wide reprogramming

  • Frédérik Oger,
  • Maeva Moreno,
  • Mehdi Derhourhi,
  • Bryan Thiroux,
  • Lionel Berberian,
  • Cyril Bourouh,
  • Emmanuelle Durand,
  • Souhila Amanzougarene,
  • Alaa Badreddine,
  • Etienne Blanc,
  • Olivier Molendi-Coste,
  • Laurent Pineau,
  • Gianni Pasquetti,
  • Laure Rolland,
  • Charlène Carney,
  • Florine Bornaque,
  • Emilie Courty,
  • Céline Gheeraert,
  • Jérôme Eeckhoute,
  • David Dombrowicz,
  • Julie Kerr-Conte,
  • François Pattou,
  • Bart Staels,
  • Philippe Froguel,
  • Amélie Bonnefond,
  • Jean-Sébastien Annicotte

Journal volume & issue
Vol. 26, no. 7
p. 107231

Abstract

Read online

Summary: Histone deacetylases enzymes (HDACs) are chromatin modifiers that regulate gene expression through deacetylation of lysine residues within specific histone and non-histone proteins. A cell-specific gene expression pattern defines the identity of insulin-producing pancreatic β cells, yet molecular networks driving this transcriptional specificity are not fully understood. Here, we investigated the HDAC-dependent molecular mechanisms controlling pancreatic β-cell identity and function using the pan-HDAC inhibitor trichostatin A through chromatin immunoprecipitation assays and RNA sequencing experiments. We observed that TSA alters insulin secretion associated with β-cell specific transcriptome programming in both mouse and human β-cell lines, as well as on human pancreatic islets. We also demonstrated that this alternative β-cell transcriptional program in response to HDAC inhibition is related to an epigenome-wide remodeling at both promoters and enhancers. Our data indicate that HDAC activity could be required to protect against loss of β-cell identity with unsuitable expression of genes associated with alternative cell fates.

Keywords